Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27028519 | 1.00 | THRB (0.55) | THRBALDH1A1TSHRLMNACYP2C19 | |
| SCHEMBL8968 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL7537660 | 0.94 | — | — | |
| Water SCHEMBL11045586 | 0.94 | — | — | |
| SCHEMBL1163579 | 0.94 | THRB (0.50) | THRBALDH1A1TSHRLMNA | |
| Water SCHEMBL3827178 | 0.94 | THRB (0.50) | THRBALDH1A1TSHRLMNA | |
| SCHEMBL129302 | 0.94 | — | — | |
| SCHEMBL402114 | 0.94 | THRB (0.50) | THRBALDH1A1TSHRLMNA | |
| SCHEMBL21494164 | 0.94 | THRB (0.50) | THRBALDH1A1TSHRLMNA | |
| Ammonia Solution, Strong SCHEMBL8694521 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940283-B2 | Cosmetic composition comprising at least one cationic poly(vinyllactam), at least one fatty alcohol, and at least one polyol, cosmetic process for treating keratin fibers and use of the composition | L'OREAL (FR) | 2015-01-27 | — | — | US | claimed |
| US-20060128575-A1 | Traction fluid composition | GEIGER RENE | 2006-06-15 | — | — | US | claimed |
| EP-3790867-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112513020-B | KDM1A inhibitors for the treatment of diseases | 伊美格生物科学公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117466884-A | Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof | 德州大学系统董事会 | 2024-01-30 | — | — | CN | disclosed |
| CN-112218631-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-12-22 | — | — | CN | disclosed |
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111867590-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-11-17 | — | — | CN | disclosed |
| EP-3947384-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-01 | — | — | EP | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20040138175-A1 | Boronic acid salts useful in parenteral formulations | TRIGEN LIMITED | 2004-07-15 | — | — | US | disclosed |
| EP-1400245-A1 | Boronic acid salts useful in parenteral formulations for selective thrombin inhibition | TRIGEN LIMITED (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004022072-A1 | BORONIC ACID SALTS ANT THEIR USE IN THE TREATMENT OF THROMBOSIS | TRIGEN LIMITED (GB) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022071-A1 | MULTIVALENT METAL SALTS OF BORONIC ACIDS FOR TREATING THROMBOSIS | TRIGEN LIMITED (GB) | 2004-03-18 | — | — | WO | disclosed |
| EP-1396270-A1 | Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis | TRIGEN LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1396269-A1 | Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis | TRIGEN LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| US-6329489-B1 | CONTACTING UNSYMMETRICAL DIFUNCTIONAL SILANE MONOMERS WITH WATER, WITH DIOL MONOMERS TO PRODUCE REACTIVE SILANE OLIGOMER | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| CN-1243551-A | Electrochemical cell and electrochemical system | ELECTROLYSER CORP LTD (CA) | 2000-02-02 | — | — | CN | disclosed |
| US-3984294-A | ELECTROLYTIC HYDRODIMERIZATION OF ACETONE | BASF AKTIENGESELLSCHAFT (DT) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | THRB 3400/4885ALDH1A1 839/4885TSHR 4447/4885 |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | THRB 3400/4885ALDH1A1 839/4885TSHR 4447/4885 |
| US-20040138175-A1 | Boronic acid salts useful in parenteral formulations | HBZ, BPGM, GCG | THRB 190/4885ALDH1A1 4879/4885TSHR 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.